Mylan Inc. has starting shipping desloratadine tablets (5 mg), an allergy medication, and carbonate extended-release tablets (300 mg), a treatment for manic episodes of bipolar disorder.


Mylan, generic version, Clarinex, Lithobid, desloratadine tablets, carbonate extended-release tablets, Mylan Pharmaceuticals, allergy medication, bipolar disorder, Schering-Plough, Noven Therapeutic
































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan releases generics of Clarinex, Lithobid

July 3rd, 2012

PITTSBURGH – Mylan Inc. has starting shipping desloratadine tablets (5 mg), an allergy medication, and carbonate extended-release tablets (300 mg), a treatment for manic episodes of bipolar disorder.

The company said Tuesday that both products were released by its Mylan Pharmaceuticals Inc. subsidiary, Mylan said Tuesday.

Mylan's desloratadine tablets are a generic version of Schering-Plough's Clarinex allergy medicine, while its carbonate extended-release tablets are a generic version of Noven Therapeutic's Lithobid tablets.

In the United States, desloratadine tablets (5 mg) had sales of $194.6 million and lithium carbonate ER tablets had sales of about $21 million for the 12 months ended March 31, according to IMS Health figures cited by Mylan.

Advertisement